Drug class profile · refreshed daily from federal data

Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor

3 molecules in this class, $3.1M combined CY2024 Part D spend across 114 claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 15 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $3.1Mcombined across class
Total Rx claims: 11423 unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Sofosbuvir

Brand: Sovaldi · 114 Part D claims (CY24) · 23 beneficiaries · First FDA approval: 2013-12-06

Brand-only (no generics) 17 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $3.1M

Class share

100%

of class CY24 spend

View profile →

Sofosbuvir, Velpatasvir, and Voxilaprevir

Brand: Vosevi · — Part D claims (CY24) · First FDA approval: 2017-07-18

Brand-only (no generics) 302 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Velpatasvir and Sofosbuvir

Brand: Epclusa · — Part D claims (CY24) · First FDA approval: 2016-06-28

Brand-only (no generics) 717 plans require PA

Low NADAC$278.25

→

Avg plan cost$572.10

Part D spend — 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.